Literature DB >> 11053965

Lymphocyte subset proportions in Guillain-Barré syndrome patients treated with plasmapheresis.

F Yoshii1, Y Shinohara.   

Abstract

We examined the changes in the proportions of certain T cell subsets in 18 Guillain-Barré syndrome patients treated with plasmapheresis (PP). PP was performed within 8 days after the onset using a continuous-flow blood cell separator or immunoadsorption. The proportions of CD3+, CD4+ and CD4+CD45RA+ cells at the onset were decreased and that of CD19+ was increased compared with those of 25 normal controls. However, the proportions of CD4+CD45R-, CD4+HLADR+, CD4+CD25+ cells and the CD8+ subpopulations were similar in patients and controls. After PP, the altered subsets tended to normalize, particularly in the group that improved after PP. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 11053965     DOI: 10.1159/000008227

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  4 in total

1.  Can plasma exchange therapy induce regulatory T lymphocytes in multiple sclerosis patients?

Authors:  A Jamshidian; M Gharagozloo
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

3.  Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome.

Authors:  Hao Wang; Li Li; Yin Zhang; Shu-Chao Pan; An-Qiang Chen; Wei-Dong Qian
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  Therapeutic apheresis in kidney transplantation: An updated review.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Transplant       Date:  2019-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.